Last updated: September 29, 2026
Propoxyphene napsylate/acetaminophen has no credible U.S. commercial opportunity as an active analgesic combination. The FDA requested withdrawal of propoxyphene products in 2010 after data showed dose-related cardiac toxicity, including QT prolongation, QRS widening, and increased risk of serious arrhythmia. Excipients cannot address those active-ingredient risks. Any present-day value is limited to historical IP analysis, regulatory intelligence, analytical reference materials, or research involving safer replacement combinations.
Propoxyphene Napsylate and Acetaminophen Excipient Strategy and Commercial Opportunities
What was propoxyphene napsylate and acetaminophen?
Propoxyphene napsylate and acetaminophen was a fixed-dose opioid analgesic combination marketed in the United States under names including Darvocet-N and Darvon-N. The product combined the opioid propoxyphene napsylate with acetaminophen, generally in immediate-release tablets.
A representative Darvocet-N tablet contained:
| Component |
Typical amount |
| Propoxyphene napsylate |
100 mg |
| Acetaminophen |
650 mg |
The product was intended for short-term treatment of mild to moderate pain. Propoxyphene was a Schedule IV controlled substance in the United States before its withdrawal. Acetaminophen added analgesic activity but also created a separate hepatotoxicity concern when patients exceeded recommended doses or combined products containing acetaminophen.
The FDA requested market withdrawal in November 2010 after a new electrocardiographic study showed that propoxyphene caused clinically meaningful changes in cardiac conduction at therapeutic doses. The agency concluded that the safety risk outweighed the modest analgesic benefit (U.S. Food and Drug Administration [FDA], 2010a, 2010b).
What is the current FDA regulatory status of propoxyphene combinations?
Propoxyphene-containing prescription products are no longer marketed in the United States. The FDA stated that manufacturers should voluntarily withdraw propoxyphene products and that the agency would pursue formal withdrawal if necessary (FDA, 2010a).
| Regulatory issue |
Status |
| U.S. marketing |
Withdrawn |
| FDA-approved active combination |
No current commercial product |
| Opioid scheduling |
Historically Schedule IV |
| FDA exclusivity |
Expired or no longer commercially relevant |
| Generic launch pathway |
Commercially blocked by product withdrawal |
| Orange Book relevance |
Historical only for withdrawn products |
| Primary safety issue |
Cardiac conduction abnormalities |
| Secondary safety issue |
Acetaminophen overdose and liver injury |
The European Medicines Agency recommended withdrawal of propoxyphene-containing medicines from the European Union in 2009 because the benefits did not outweigh the risks, particularly the narrow margin between therapeutic and toxic doses (European Medicines Agency [EMA], 2009). The United Kingdom had already taken action against co-proxamol, a propoxyphene and acetaminophen product, because of overdose toxicity and suicide risk (Medicines and Healthcare products Regulatory Agency [MHRA], 2005).
What excipients were used in historical propoxyphene-acetaminophen tablets?
Historical immediate-release formulations used conventional solid-dose excipients. Public labeling for Darvocet-N identified inactive ingredients such as lactose, starch, magnesium stearate, talc, and coloring agents, although the precise composition varied by manufacturer and strength.
| Excipient class |
Likely formulation role |
| Lactose or other filler |
Tablet mass and manufacturability |
| Pregelatinized or native starch |
Binder and disintegrant |
| Magnesium stearate |
Lubrication |
| Talc |
Glidant or anti-adherent |
| Colorants |
Product identification |
| Film coating, where used |
Appearance, handling, and moisture barrier |
The formulation challenge was not simply tablet manufacture. It was the reliable delivery of a controlled opioid with a high-dose analgesic component while maintaining content uniformity, mechanical strength, rapid disintegration, and acceptable dissolution.
For an immediate-release product, an excipient program would normally prioritize:
- Uniform distribution of the lower-dose propoxyphene component.
- Rapid release of both active ingredients.
- Low interaction risk between the napsylate salt and excipients.
- Robust compression at commercial scale.
- Stable assay and dissolution during shelf life.
- Low moisture uptake and controlled impurity formation.
What excipient strategy would be technically suitable for the formulation?
A conventional direct-compression or dry-granulation platform would be the most defensible starting point for an immediate-release tablet. Wet granulation could improve content uniformity and flow but would add water, heat, and processing complexity.
Direct compression
Direct compression could use a co-processed filler-binder, a disintegrant, a lubricant, and a glidant. The principal development risk would be segregation caused by differences in particle size, density, and loading between propoxyphene napsylate and acetaminophen.
A suitable development strategy would include:
- Particle-size control for both active ingredients.
- Ordered mixing or pre-blending of the lower-dose opioid component.
- A high-functionality filler-binder to improve tablet strength.
- A superdisintegrant at a controlled level.
- Minimal lubricant exposure to avoid dissolution delay.
- Blend-uniformity testing at commercial batch scale.
Dry granulation
Roller compaction could reduce segregation and improve flow without introducing water. It would be useful if the active ingredients had poor flow or if the opioid content required tighter blend control. The process could, however, produce harder granules and slower disintegration if compaction force was excessive.
Wet granulation
Wet granulation would be considered only if direct compression and dry granulation failed to deliver uniformity or tablet robustness. Water exposure would require stability studies for:
- Propoxyphene-related degradation products.
- Acetaminophen degradation.
- Changes in dissolution.
- Color and appearance.
- Residual moisture.
Coating
A conventional film coat could improve handling, taste, and identification. It would not create a meaningful safety advantage unless paired with a substantially different delivery system. A standard immediate-release film coat could also delay dissolution if polymer load or coating weight were excessive.
What formulation patents could protect propoxyphene napsylate and acetaminophen?
The original product’s formulation and manufacturing patents are unlikely to provide meaningful current exclusivity. Products marketed in the 1970s, 1980s, and 1990s would generally have lost ordinary U.S. patent term, and the FDA withdrawal removed the commercial value of any residual product-specific rights.
Potential historical claim categories included:
| Claim category |
Commercial relevance today |
| Propoxyphene salt selection |
Expired or commercially obsolete |
| Fixed-dose tablet composition |
Expired or commercially obsolete |
| Immediate-release dosage form |
Limited technical value |
| Manufacturing process |
Potentially expired and difficult to enforce |
| Stability or packaging system |
Limited value without lawful marketing |
| Method of treating pain |
Expired or subordinate to withdrawal |
| Abuse-deterrent formulation |
Possible new IP category but limited by active-ingredient toxicity |
A new patent could theoretically cover a novel formulation, delivery system, particle engineering method, or manufacturing process. Patentability would not solve the central regulatory problem. A new formulation would still require a viable benefit-risk profile and regulatory authorization for a withdrawn active ingredient.
When does propoxyphene lose exclusivity and what does that mean for generics?
Propoxyphene lost practical market exclusivity before its withdrawal. Generic versions were marketed, and the product did not depend on a current patent barrier for commercial protection. The decisive barrier became FDA safety action rather than patent expiration.
A generic manufacturer cannot create a viable launch opportunity merely by using a different excipient system. The applicant would face:
- The safety basis for withdrawal.
- The need for an approvable reference product or an acceptable regulatory pathway.
- Controlled-substance requirements.
- Opioid labeling and postmarket obligations.
- Acetaminophen toxicity considerations.
- Commercial reluctance to launch a product with a withdrawn reference profile.
Paragraph IV litigation is therefore not a meaningful current risk category for this product. Any historic Paragraph IV disputes would have lost commercial importance after the FDA withdrawal. A new applicant would not gain a practical advantage from avoiding expired patents because approval and market acceptance are the dominant obstacles.
What is the Orange Book status of propoxyphene napsylate and acetaminophen?
The Orange Book value of the product is historical. The relevant questions are whether an approved reference listed drug remains commercially active, whether patents or exclusivity remain listed, and whether a generic can rely on that reference product.
For propoxyphene-acetaminophen products, the withdrawal of U.S. marketing eliminated the normal commercial pathway associated with an active reference product. Historical listings, discontinued products, and old patent entries do not create a current opportunity comparable to a marketed branded product with live Orange Book patents.
The practical conclusion is:
- No current branded reference-product opportunity exists.
- No meaningful current patent-cliff opportunity exists.
- An abbreviated generic strategy would face regulatory and commercial obstacles beyond excipient selection.
- A 505(b)(2) strategy would still require a persuasive safety and benefit-risk case.
What patent litigation and settlement agreements affected the product?
The principal commercial issue was regulatory withdrawal, not an active patent conflict. Publicly important litigation involving propoxyphene centered on alleged injury, dependence, overdose, and cardiac risks rather than a current patent dispute over excipients or formulation design.
No current settlement-driven generic-entry opportunity is apparent from the product’s withdrawal history. A settlement permitting generic entry would have little value when the branded and generic products themselves have been removed from the U.S. market.
What commercial opportunities remain for excipient suppliers?
The direct commercial opportunity is weak. Excipient suppliers should not treat propoxyphene-acetaminophen as a viable near-term product platform.
Potential residual opportunities are limited to:
Analytical and reference-material applications
Research organizations may require historical formulations, impurity standards, dissolution references, or excipient compatibility data. This is a small specialty market rather than a drug-launch opportunity.
Archive, litigation, and forensic work
Historical tablets and formulation reconstruction may support product-liability litigation, regulatory investigations, or forensic toxicology. The demand is episodic.
Reformulation know-how transferred to safer products
The most commercially useful assets are transferable formulation capabilities:
- Low-dose active uniformity.
- High-dose acetaminophen compression.
- Rapid-disintegrating immediate-release tablets.
- Moisture-controlled manufacturing.
- Taste masking.
- Abuse-deterrent processing.
- Robust analytical methods.
These capabilities can be applied to active ingredients with a viable regulatory profile, but they do not revive propoxyphene.
Non-U.S. markets
Non-U.S. availability has also been severely restricted. The EMA’s withdrawal recommendation and the MHRA’s action against co-proxamol materially reduced the addressable market. Country-specific residual supply, if any, would not support a broad multinational strategy without current regulatory authorization and pharmacovigilance infrastructure.
How does propoxyphene-acetaminophen compare with safer analgesic combinations?
| Product category |
Patent opportunity |
Regulatory position |
Commercial outlook |
| Propoxyphene plus acetaminophen |
Mostly expired or irrelevant |
Withdrawn in major markets |
Poor |
| Tramadol plus acetaminophen |
May have formulation or method-of-use opportunities |
Marketed in some jurisdictions |
Moderate, subject to opioid controls |
| Hydrocodone plus acetaminophen |
Historical formulation and method patents |
Marketed under controlled-substance rules |
Established but highly regulated |
| Oxycodone plus acetaminophen |
Formulation and abuse-deterrence opportunities |
Marketed, with substantial scrutiny |
Established but exposed to opioid-policy risk |
| Non-opioid combinations |
Formulation and delivery opportunities |
Generally more favorable |
Stronger long-term opportunity |
The most attractive replacement strategy is not a new excipient system for propoxyphene. It is a non-opioid or lower-risk analgesic platform that uses the same manufacturing competencies without retaining propoxyphene’s cardiac liability.
What generic launch risks exist for propoxyphene-acetaminophen?
A hypothetical generic launch would face five major risks:
- Regulatory non-acceptance because of the active ingredient’s established safety profile.
- Lack of a commercially viable U.S. reference-product pathway.
- Controlled-substance compliance costs.
- Product-liability exposure.
- Limited prescriber and payer demand after withdrawal.
Excipient differentiation would have little impact on these risks. A lactose-free, low-moisture, rapidly disintegrating, or abuse-deterrent tablet would still contain the same cardiotoxic active ingredient.
How strong is the patent estate for propoxyphene napsylate and acetaminophen?
The current patent estate is commercially weak. The product is an old fixed-dose combination, and the principal barriers are regulatory and medical rather than intellectual property.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Original formulation protection |
Expired or immaterial |
| Current Orange Book leverage |
None of practical commercial value |
| New excipient patent potential |
Technically possible, commercially weak |
| Method-of-use protection |
Expired or overridden by withdrawal |
| Manufacturing patent value |
Low without approved market |
| Freedom-to-operate concern |
Secondary to regulatory viability |
Key Takeaways
- Propoxyphene napsylate/acetaminophen was withdrawn from the U.S. market in 2010 because of cardiac safety risks.
- Excipients cannot mitigate propoxyphene-induced QT prolongation, QRS widening, or arrhythmia risk.
- Historical formulations used standard immediate-release tablet excipients, including fillers, starch-based disintegrants or binders, magnesium stearate, talc, and colorants.
- The product’s patent and exclusivity position is commercially obsolete.
- Paragraph IV litigation and generic-entry analysis have little current relevance.
- The strongest residual value lies in analytical, forensic, archival, or formulation-know-how applications.
- Excipient companies should redirect development capabilities toward safer analgesics and non-opioid fixed-dose combinations.
- A new propoxyphene formulation would face a regulatory problem, not an excipient problem.
FAQs
Can a new excipient make propoxyphene safer?
No. Excipients may improve manufacturability, dissolution, stability, or abuse resistance, but they do not remove the active ingredient’s cardiac conduction risk.
Is propoxyphene-acetaminophen still available as a generic?
It is not a viable U.S. generic commercial product following the FDA-requested withdrawal of propoxyphene products.
Could an abuse-deterrent formulation revive propoxyphene?
An abuse-deterrent design would not address the primary reason for withdrawal, which was cardiac toxicity at therapeutic exposure. It would also add development cost without creating a clear regulatory pathway.
Are propoxyphene formulation patents still valuable?
Historical patents may have archival or litigation relevance, but they do not provide meaningful commercial exclusivity for a withdrawn product.
What is the best replacement opportunity for an excipient developer?
The stronger opportunity is to transfer the formulation platform to safer non-opioid analgesics, lower-risk combination products, or controlled-release systems with an active ingredient that has a current regulatory and commercial pathway.
References
-
European Medicines Agency. (2009). European Medicines Agency recommends the withdrawal of dextropropoxyphene-containing medicines. https://www.ema.europa.eu/
-
Medicines and Healthcare products Regulatory Agency. (2005). Co-proxamol: withdrawal of marketing authorisations. https://www.gov.uk/
-
U.S. Food and Drug Administration. (2010a). FDA recommends against continued use of propoxyphene. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2010b). FDA drug safety communication: FDA requires withdrawal of propoxyphene from the market. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/ index.cfm
